Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03314987 · ClinicalTrials.gov registry record · NA
Nucleophilic Defense Against PM Toxicity (NEAT Trial)
A NA study of Air Pollution Toxicity, sponsored by University of Louisville.
- Completed
- Registry status
- NA
- Development phase
- 299
- Enrollment target
- 1
- Study location
NCT03314987: Completed NA study of Air Pollution Toxicity, sponsored by University of Louisville.
NCT03314987 is a NA study of Air Pollution Toxicity that has completed, run by University of Louisville. The registered enrollment target is 299 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03314987, a NA study of Air Pollution Toxicity, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- NA
- Development phase
- 299 participants
- Enrollment target
- 1
- Study location
Study Summary
Carnosine is a naturally occurring peptide found in high levels in skeletal muscle and the brain and is also available commercially as a dietary supplement. Since carnosine has anti-oxidant properties and air pollution exposure induces a state of oxidative stress, the purpose of this study is to see if those taking carnosine as a dietary supplement are protected from air pollution-induced oxidative stress and adverse cardiovascular outcomes.
Primary Outcome
circulating pro-angiogenic cells
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT L-carnosine
Study Locations (1)
Kentucky
- Clinical Trials Unit - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2022-11-01 |
| Phase | NA |
What the finished NCT03314987 record still lists
NCT03314987 is an interventional study that assigns participants to a tested intervention. The registered 299 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Air Pollution Toxicity appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT03314987 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03314987 about?
NCT03314987 is a clinical study titled "Nucleophilic Defense Against PM Toxicity (NEAT Trial)". Carnosine is a naturally occurring peptide found in high levels in skeletal muscle and the brain and is also available commercially as a dietary supplement. Since carnosine has anti-oxidant properties and air pollution exposure induces a state of oxidative stress, the purpose of this study is to see...
What is the current status of trial NCT03314987?
This trial is currently completed. It is a NA study. The enrollment target is 299 participants. The study started on 2018-04-01. Estimated completion is 2022-11-01.
What conditions does trial NCT03314987 study?
This clinical trial studies the following conditions: Air Pollution Toxicity.
What interventions are being tested in trial NCT03314987?
The interventions under investigation include: placebo (OTHER), L-carnosine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03314987?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03314987 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03314987's enrollment target sits among peer trials
299 371st of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI